These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 8822501)

  • 21. Fundamental research leading to improved endocrine therapy for breast cancer.
    Miller WR
    J Steroid Biochem; 1987; 27(1-3):477-85. PubMed ID: 3320538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Benefits of complete polyamine deprivation in hormone responsive and hormone resistant MCF-7 human breast adenocarcinoma in vivo.
    Leveque J; Foucher F; Havouis R; Desury D; Grall JY; Moulinoux JP
    Anticancer Res; 2000; 20(1A):97-101. PubMed ID: 10769640
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New hormonal approaches to the treatment of breast cancer.
    Hamm JT; Allegra JC
    Crit Rev Oncol Hematol; 1991; 11(1):29-41. PubMed ID: 1652976
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients.
    Mandalà M; Moro C; Ferretti G; Calabro MG; Nolè F; Rocca A; Munzone E; Castro A; Curigliano G
    Anticancer Res; 2001; 21(1B):585-8. PubMed ID: 11299809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endocrine treatment of advanced breast cancer.
    Dowsett M
    Acta Oncol; 1996; 35 Suppl 5():68-72. PubMed ID: 9142970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Letrozole vs. placebo after adjuvant tamoxifen in postmenopausal breast cancer. The example of the MA-17 study].
    Forciniti S
    Suppl Tumori; 2004; 3(4):S25-6. PubMed ID: 15206205
    [No Abstract]   [Full Text] [Related]  

  • 27. [Letrozole vs. placebo after adjuvant tamoxifen in postmenopausal breast cancer: the MA-17 study].
    Gori S; Anastasi P; Marrocolo F
    Suppl Tumori; 2004; 3(4):S27-31. PubMed ID: 15206206
    [No Abstract]   [Full Text] [Related]  

  • 28. [Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
    de Cremoux P; Diéras V; Poupon MF; Magdelénat H; Sigal-Zafrani B; Fourquet A; Pierga JY
    Bull Cancer; 2004 Dec; 91(12):917-27. PubMed ID: 15634633
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The nature of tamoxifen action in the control of female breast cancer.
    Kodama M; Kodama T
    In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer.
    Colleoni M; Munzone E
    Drugs; 2015 Aug; 75(12):1311-21. PubMed ID: 26177891
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The regulation of estrogen receptor expression and function in human breast cancer.
    Ferguson AT; Lapidus RG; Davidson NE
    Cancer Treat Res; 1998; 94():255-78. PubMed ID: 9587692
    [No Abstract]   [Full Text] [Related]  

  • 32. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
    Howell A; Howell SJ; Clarke R; Anderson E
    J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):227-37. PubMed ID: 11850229
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A pure antiestrogen, ICI 182,780, stimulates the growth of tamoxifen-resistant KPL-1 human breast cancer cells in vivo but not in vitro.
    Kurebayashi J; Otsuki T; Yamamoto S; Kurosumi M; Nakata T; Akinaga S; Sonoo H
    Oncology; 1998 Dec; 55 Suppl 1():23-34. PubMed ID: 9852399
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Update on endocrine therapy for breast cancer.
    Buzdar AU; Hortobagyi G
    Clin Cancer Res; 1998 Mar; 4(3):527-34. PubMed ID: 9533518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endocrine therapies of breast cancer.
    Goldhirsch A; Gelber RD
    Semin Oncol; 1996 Aug; 23(4):494-505. PubMed ID: 8757275
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
    J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oestrogen suppression--lessons from clinical studies.
    Lønning PE
    Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):33-45. PubMed ID: 14687596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [New developments in hormonal therapy for breast cancer].
    Tominaga T
    Gan To Kagaku Ryoho; 1996 May; 23(6):678-83. PubMed ID: 8645017
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens.
    Brodie AH; Jelovac D; Long B
    J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):283-8. PubMed ID: 14623522
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hormone-resistant breast cancer or "feeding the hand that bites you".
    Horwitz KB
    Prog Clin Biol Res; 1994; 387():29-45. PubMed ID: 7972253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.